
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBio Therapeutics’ (NASDAQ:LOGC) Investigational New Drug Application (IND) of its drug candidate LB-001 for pediatric patients with methylmalonic acidemia.

The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBio Therapeutics’ (NASDAQ:LOGC) Investigational New Drug Application (IND) of its drug candidate LB-001 for pediatric patients with methylmalonic acidemia.